- Home
- NBH vs ALLO Comparison
NBH vs ALLO Comparison
Compare NBH & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBH
- ALLO
- Stock Information
- Founded
- NBH 2002
- ALLO 2017
- Country
- NBH United States
- ALLO United States
- Employees
- NBH N/A
- ALLO N/A
- Industry
- NBH Finance/Investors Services
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NBH Finance
- ALLO Health Care
- Exchange
- NBH Nasdaq
- ALLO Nasdaq
- Market Cap
- NBH 288.5M
- ALLO 277.8M
- IPO Year
- NBH N/A
- ALLO 2018
- Fundamental
- Price
- NBH $9.87
- ALLO $1.30
- Analyst Decision
- NBH
- ALLO Strong Buy
- Analyst Count
- NBH 0
- ALLO 9
- Target Price
- NBH N/A
- ALLO $8.44
- AVG Volume (30 Days)
- NBH 85.9K
- ALLO 3.2M
- Earning Date
- NBH 01-01-0001
- ALLO 08-06-2025
- Dividend Yield
- NBH 4.34%
- ALLO N/A
- EPS Growth
- NBH N/A
- ALLO N/A
- EPS
- NBH 0.12
- ALLO N/A
- Revenue
- NBH N/A
- ALLO N/A
- Revenue This Year
- NBH N/A
- ALLO N/A
- Revenue Next Year
- NBH N/A
- ALLO $199.63
- P/E Ratio
- NBH $87.04
- ALLO N/A
- Revenue Growth
- NBH N/A
- ALLO N/A
- 52 Week Low
- NBH $8.75
- ALLO $0.86
- 52 Week High
- NBH $11.01
- ALLO $3.78
- Technical
- Relative Strength Index (RSI)
- NBH 47.91
- ALLO 46.23
- Support Level
- NBH $9.79
- ALLO $1.13
- Resistance Level
- NBH $9.97
- ALLO $1.26
- Average True Range (ATR)
- NBH 0.06
- ALLO 0.08
- MACD
- NBH 0.01
- ALLO -0.00
- Stochastic Oscillator
- NBH 44.44
- ALLO 43.18
About NBH Neuberger Berman Municipal Fund Inc.
Neuberger Berman Municipal Fund Inc is a closed-end management investment company that invests mainly in municipal securities. The company aims to provide common stockholders a high level of current income exempt from Federal income tax.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.